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Background: Human epididymis protein 4 (HE4) is a novel and specific biomarker for ovarian cancer. The aim of
this study is to evaluate a new tumor marker, HE4, in comparison with CA125 in diagnosis of epithelial ovarian
cancer (EOC) and benign gynecological diseases.
Methods: CA125 and HE4 serum levels were determined in 30 patients with epithelial ovarian cancer (21 serous, 6
endometrioid and 3 mucinous tumors), 20 patients with benign gynecological diseases (8 patients with ovarian
cyst, 5 patients with endometriosis, 4 patients with fibroid and 3 patients with pelvic inflammatory disease) and 20
healthy women. CA125 and HE4 cut-offs were 35 U/ml and 150 pmol/l, respectively.
Results: Serum HE4 and CA125 concentrations were significantly higher in the ovarian cancer patients compared
with those seen in patients with benign disease or in the healthy controls (p = 0.001 and p < 0.001 respectively). In
the receiver operating characteristic analysis (ROC), the area under the curve (AUC) values for HE4 was 0.96 (95%
confidence interval, 0.9-1.0) and CA125 was 0.82 (95% confidence interval, 0.7-0.94). Compared to CA125, HE4 had
higher sensitivity (90% vs. 83.3%), specificity (95% vs. 85%), PPV (93.1% vs. 80.7%) and NPV (92.7% vs. 87.2%), the
combination of HE4 + CA125 the sensitivity and PPV reached 96.7% and 97% respectively.
Conclusion: Measuring serum HE4 concentrations along with CA125 concentrations may provide higher accuracy
for detecting epithelial ovarian cancer.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1060413168685759
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The annual incidence of ovarian cancer is 204,000, with
125,000 deaths. In developed countries, ovarian cancer
remains the most lethal of all gynecologic malignancies.
One of the reasons for the high fatality rate is that more
than 70% of women with ovarian cancer are diagnosed
with advanced disease. There is a close correlation be-
tween stage at presentation and survival; therefore, early
detection of ovarian cancer represents the best hope for
mortality reduction and long term disease control. There* Correspondence: elhamomar@yahoo.com
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reproduction in any medium, provided the oris preliminary evidence that screening can improve sur-
vival, but the impact of screening on mortality from
ovarian cancer is still unclear [1].
Epithelial ovarian cancer set by the World Health
Organization (WHO) recognizes eight histological tumor
subtypes: serous, mucinous, endometrioid, clear cell, transi-
tional cell, squamous cell, mixed epithelial and undifferenti-
ated. Within each subtype, tumors are further described as
benign, malignant, or borderline, and depending upon
tumor subtype; classified as low or high-grade. Borderline
tumors are considered to have low malignant potential
and/or indolent behavior [2].
Serous tumors, which carry the poorest prognosis, are
the most common form of ovarian carcinoma and makeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cally similar to cancers of the fallopian tube, and range
from cystic papillary tumors to solid masses. Endome-
trioid tumors, accounting for 10-20% of ovarian carcin-
omas, are characterized by endometrial-like glandular
structures. Mucinous tumors often contain cysts and
glands lined by mucin-rich cells and constitute 5-20% of
ovarian carcinomas. Clear cell tumors represent 3-10%
of ovarian carcinomas and are comprised of clear and
hobnailed cells with an immature glomerular pattern.
Undifferentiated carcinomas constitute 1% [3].
Recent morphologic, immunohistochemical, and mo-
lecular genetic studies have led to the development of a
new paradigm for the pathogenesis and origin of epithelial
ovarian cancer based on a dualistic model of carcinogen-
esis that divides epithelial ovarian cancer into 2 broad cat-
egories designated types I and II. Type I tumors include all
major histotypes (serous, endometrioid, mucinous, clear
cell, and transitional) but exhibit low-grade nuclear and
architectural features, slow growth, and can be linked to
well-defined benign ovarian precursor lesions. They are
generally indolent, present in stage I (tumor confined to
the ovary), and are characterized by specific mutations, in-
cluding KRAS, BRAF, ERBB2, CTNNB1, PTEN, PIK3CA,
ARID1A, and PPP2R1A. Type II tumors comprise high-
grade serous, high-grade endometrioid, malignant mixed
mesodermal tumors (carcinosarcomas), and undifferenti-
ated carcinomas. They are aggressive, present in advanced
stage, and have a very high frequency of TP53 mutations
and may also exhibit gene amplification and overexpression
of HER2/neu and AKT2 oncogenes [4]. Several protoonco-
genes, tumor suppressor genes, and apoptosis related genes
including bax, bcl-2, p53, p21, myc, c-kit, telomerase, and
metallothionein have been investigated in ovarian tumors
which can reliably predict the rate of progression and the
response to chemotherapy and can facilitate ovarian cancer
typing [5-8]. Recent Immunohistochemical staining of ovar-
ian cancer for potassium channels (Kv1.3, K2p9.1, Eag and
HERG) have been shown to be overexpressed in ovarian
cancer where they appear to play a role in cell proliferation
and progression [9].
Symptoms of epithelial ovarian cancer are often nonspe-
cific, especially in early stage cancer. Ultrasound is used to
assess patients for ovarian cancer; ultrasound has a low
specificity for determining if a mass is benign or malig-
nant. The specificity is improved by using Doppler ultra-
sound and a morphology index but performance varies
amongst different operators [10].
The use of tumor markers to further characterize the
mass has come into clinical use. Carbohydrate antigen
125 (CA125) is the most widely used tumor marker in
ovarian cancer; however, its predictive power is far from
ideal. It is elevated in about 80% of women with epithe-
lial ovarian cancer (EOC) but only in 50% of womenwith early stage disease [11]. The specificity of CA125 is
limited, since it can be elevated in a range of common
benign gynecologic or non-gynecologic conditions [12].
Furthermore, the sensitivity and specificity of CA125 are
not high enough for population screening for the detec-
tion of early stage ovarian cancer [13].
The identification of new cancer biomarkers to replace
or complement CA125 is urgently needed and currently
underway. Accordingly, there have been many efforts to
improve the diagnostic performance of markers or marker
combinations, and some markers, including mesothelin,
CA72-4, inhibin, kallikreins, and osteopontin, have been
investigated to complement CA125 and to improve its
sensitivity for early detection [12,14]. Among these,
human epididymis protein 4 (HE4), also known as WAP-
type four disulphide core 2 (WFDC2), is one of the most
promising markers for improving the sensitivity and speci-
ficity. HE4 is primarily expressed in the reproductive and
respiratory tracts [15] and is overexpressed in ovarian can-
cer cells, especially in histologic subtypes of serous or
endometriod carcinoma [16] and it has been suggested to
be a serological marker of ovarian cancer [17]. In this
study, we aimed to compare the characteristics of HE4
and CA125 in epithelial ovarian cancer and benign
gynecological diseases, and to evaluate the diagnostic per-
formance of both CA125 and HE4 in discriminating ovar-
ian cancer from other benign gynecologic diseases.Methods
Subjects and study design
In this study, 30 female patients were selected with re-
cently diagnosed malignant epithelial ovarian cancers,
who consecutively were admitted at Oncology department
in Sohag University from March 2011 to July 2012. The
inclusion criteria were: availability of complete clinical
records, informed consent and agreement to have add-
itional testing for new markers, clinical and histological
diagnosis with staging and grading of ovarian cancer,
according to the current classification and guidelines. The
mean age was 50.7 ± 14.6 years (range 24-73), and 9 were
in menopause (30%). The histological diagnosis was as
follows: 21 serous (70%), 6 endometrioid (20%) and 3
mucinous tumors (10%). It was approved by the faculty
committee for research ethics. The exclusion criteria: were
pregnancy and significant concomitant diseases such as
chronic heart failure, and severe chronic liver or renal
disease. The second group consisted of 20 patients with
benign gynecological diseases, with a mean age of 45.1 ±
14.7 years (range 40-60) and 5 in menopause (25%). The
group with benign diseases included 8 patients with
ovarian cyst (40%), 5 patients with endometriosis (25%),
4 patients with fibroid (20%) and 3 patients with pelvic
inflammatory disease (15%). The third group included
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group as a control group.
Methods
Venous blood samples were collected following an over-
night fasting (serum and EDTA samples) before chemo-
therapy treatment and at 6 month intervals thereafter.
Serum glucose, liver function tests and renal function tes-
tes were analyzed on autoanalyzer Cobas c 311 (Roche/
Hitachi cobas C systems). Complete blood picture on cell
dyne-2700 fully automated cell counter. CA125 analysis
was done on Axsym system (Abbott Diagnostics Division,
Chicago) based on Microparticle Enzyme Immunoassay
(MEIA) technology. HE4 assay was performed on the fully
automated ARCHITECT instrument (Abbott Diagnostics
Division, Chicago) based on Chemiluminescentmicroparti-
cle immunoassay (CMIA). The two monoclonal antibodies
(2 H5 and 3D8) were used for capture and detection of
HE4. In the first step, sample and 2H5 anti-HE4 coated
paramagnetic microparticles are combined. HE4 antigen
present in the sample binds to the anti-HE4 coated micro-
particles. After washing, 3D8 anti-HE4 acridinium labeled
conjugate is added to create a reaction mixture in the
second step. Following another wash cycle, pre-trigger and
trigger solutions are added to the reaction mixture. The
resulting chemiluminescent reaction is measured as relative
light units. A direct relationship exists between the amount
of HE4 antigen in the sample and the relative light units.Table 1 Clinical and laboratory variables of studied groups
Ovarian cancer (n = 30) Benign g
Age (range) 24-73 40-60
Menopause% 30 25
RBCs count x1012/l 4.5 ± 0.5 4.5 ±0.49
Hb g/dl 12.1 ± 1.5 12.5 ± 1.4
WBCs x109/l 8.1 ± 2.9 6.9 ± 2.3
Platelets x109/l 270 ± 82 294.7 ± 72
S.glucose (mg/dl) 95 ± 15.4 91 ± 7.4
S.urea (mg/dl) 31.4 ± 8.9 29.1 ± 6.7
S.creatinine (mg/dl) 0.7 ± 0.15 0.7 ± 0.13
ALT (U/l) 17.4 ± 12.6 15.4 ± 11.5
AST (U/l) 24.7 ± 14.5 21.1 ± 10.4
ALP (U/l) 76.4 ± 24.2 68.5 ± 10.9
Total protein g/dl 7.6 ± 0.6 7.4 ± 0.5
Albumin g/dl 3.8 ± 0.33 3.9 ± 0.36
Total bilirubin mg/dl 0.46 ± 0.3 0.6 ± 0.26
D. bilirubin mg/dl 0.12 ± 0.07 0.11 ± 0.06
CA125 U/ml 295.5 (4.2-1781)b,c 26.9 (9.4-5
HE4 pmol/l 237.2 (34.3-4090)b,c 66.1 (24.8
Values are expressed as the mean ± standard deviation or median (range). aP < 0.05
benign gynecological dis.Statistical analysis
The data are presented as mean ± standard deviation (SD)
or median (range) and number (n). Linear relationships
between variables were determined using Spearman’s rank
correlation test. One way analysis of variance (ANOVA)
test was used followed by post hoc test to determine
the significance of variables when comparing more than
2 groups. Non-parametric receiver operating character-
istic (ROC) analyses were performed to evaluate diag-
nostic values of individual parameters generated by
graphically plotting sensitivity versus specificity with
using 95% confidence intervals (CI). The diagnostic ac-
curacy of the test is measured by the area under the
curve (AUC). Statistical significance is considered a
value of P <0.05. All statistical analyses were performed
using SPSS software, version 10.0.
Results
Clinical characteristics and laboratory variables of the
studied groups were demonstrated in Table 1. The me-
dian CA125 and HE4 levels in the healthy control were
12.5 U/ml and 56.9 pmol/l respectively. There were sig-
nificant difference in HE4 & CA125 values between the
ovarian cancer group (median 295.5 U/ml, for CA125,
and median 237.2 pmol/l, for HE4) than the benign
gynecological disease (median 26.9 U/ml, p = 0.001 for
CA125, and median 66.1 pmol/l, p = 0.001 for HE4) and
control group (p <0.001). CA125 was also higher inynecological (n = 20) Controls (n = 20) p (ANOVA)
30-66 -
20 -
4.8 ± 0.5 NS
12 ± 1.3 NS
7.6 ± 2 NS
.1 264.7 ± 59.4 NS
85 ± 9.4 NS
27.9 ± 7.9 NS
0.73 ± 0.12 NS
13.9 ± 7.2 NS
21.1 ± 6.1 NS
70.5 ± 11.3 NS
7.7 ± 0.53 NS
3.9 ± 0.29 NS
0.5 ± 0.24 NS
0.1 ± 0.06 NS
53)a 12.5 (4.1-34.3) <0.001
-179.2) 56.9 (20.8-111.6) <0.001
, bP < 0.001,with respect to the control group; cP = 0.001, with respect to
Table 3 Sensitivity, specificity, positive and negative
predictive values (PPV and NPV) for CA125, HE4, and in
combination with each other
Sensitivity Specificity PPV NPV
HE4 90% 95% 93.1% 92.7%
CA125 83.3% 85% 80.7% 87.2%
HE4 + CA125 96.7% 80% 97% 80%
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in the healthy control, but HE4 was not (p >0.05). Table 2
showed FIGO stage of the studied woman, 40% of the
patients had stage 3 and the serum levels of HE4 and
CA125 in relation to histological types with higher sig-
nificant level in serous ovarian cancer (p <0.01 and
p <0.05 respectively). In 30 women with EOC, HE4 were
significantly higher than CA125 in sensitivity and specifi-
city (90% vs 83.3% and 95% vs. 85%, respectively). Also,
the, positive predictive values (PPV) and negative predict-
ive values (NPV) for HE4 were significantly higher than
CA125 (93.1% vs. 80.7% and 92.7% vs. 87.2%, respectively).
Sensitivity and PPV were increased reached 96.7%, 97% re-
spectively when the two markers combined with each
other (Table 3). Figure 1 shows the receiver operating char-
acteristic analysis (ROC) plot for all women with epithelial
ovarian cancer and benign diseases, the area under the
curve (AUC) for CA125 was 0.82 (95% CI 0.7-0.94) and for
HE4 was 0.96 (95% CI 0.9-1.0) (p <0.01) for distinguishing
between EOC and benign disease. A positive correlation
between serum levels of HE4 and CA125 was observed in
women with epithelial ovarian cancer, benign gynecological
disease group and control group (r =0.5, p < 0.01) (Figure 2).
Of the 30 patients in the study, three were resistant to
treatment. The remaining 27 patients achieved remis-
sion determined by normalization of CA125 and HE4
levels, physical examination and imaging by computer-
ized tomography (CT) magnetic resonance imaging
(MRI) or ultrasound. Table 4 (Figure 3): show signifi-
cant difference (P < 0.001) for CA125 and HE4 levels
before and after chemotherapy. In the three patients
with persistent disease following chemotherapy and the
presence of tumor confirmed by imaging results (one
patient with omental deposit and two patients with re-
sidual tissues), CA125 and HE4 dropped but remained
above their respective thresholds thereafter.Discussion
Despite the development of new treatments and therap-
ies designed to improve the five year survival rate, ovar-
ian cancer still remains the deadliest cancer of the
female reproductive tract. Five-year survival rate is 90%Table 2 HE4 & CA125 serum levels in patients with EOC
according to tumor stage and histological type
n HE4 median (range) CA125 median (range)
Stage I-II 8 210 (55-1060) 36 (4.2-410)
Stage III 12 315 (34.3-2817) 120 (26-1300)
Stage IV 10 491 (45-4090) 320(150-1781)
Serous 21 305 (57-4090) 285 (47-1781)
Endometrioid 6 170 (34.3-1650) 137 (35-1011)
Mucinous 3 159 (142-410) 66 (4.2-405)when disease is confined to the ovaries but overall sur-
vival is poor because only 25% of cases are found in this
early stage. Unfortunately, most cases are diagnosed in
the late stages of the disease, when the five-year survival
rates fall below 20%, with most patients having meta-
static disease at presentation. This further contributes to
worsening the prognosis. The lack of precise early warn-
ing signs is one of the factors that further contribute to
the fact that only 25% of ovarian tumors are identified at
stage I [18].
CA125 is still the only tumor marker recommended as
a diagnostic or prognostic indicator and for the monitor-
ing of disease recurrence after surgery and adjuvant
chemotherapy [19-21]. The major drawback of CA125 is
the documented lack of specificity, as this marker may
show levels exceeding the 95th percentile of normal
values in a significant proportion of women with benign
or malignant diseases [22].
Accordingly, there have been many efforts to improve
the diagnostic performance of CA125. Among those, a
prominent relevance has been recently attributed to the
HE4 which is one of the most promising marker for im-
proving the sensitivity and specificity [23].
In this study, we investigated the role of HE4 alone
and in combination with CA125 in assessing patients
with epithelial ovarian cancer, regardless of the meno-
pausal status. Initial results on HE4 testing of this study
confirm the high sensitivity and specificity of this mol-
ecule over CA125 for EOC (90% vs. 83.3% and 95% vs.
85%, respectively). In our experience, no false positive
results for HE4 or CA125 were recorded on healthy
women, the specificity was more evident among patients
with benign gynecological lesions, since only 2 were posi-
tive for HE4, while 6 were positive for CA125 (10% vs
30%). we found a significant difference in CA125 values
between the benign gynecological disease group and con-
trol group (p < 0.05). Unlike CA125, HE4 was shown not
to be elevated in endometriosis [24, 25] and this may con-
tribute to the improved performance with HE4.
The diagnostic performance of CA125 and HE4 in dis-
criminating ovarian cancer from healthy and benign
gynecologic conditions was verified using ROC analysis.
The resultant AUC values were 0.96 for HE4 (95% CI
0.90-1.0) and 0.82 for CA125 (95% CI 0.70-0.94) (p < 0.01),




















Figure 1 ROC plot and AUC for CA125 and HE4 for patients with epithelial ovarian cancer and benign diseases.
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tiate ovarian cancers from healthy and benign gynecologic
conditions. This finding is in agreement with several
researchers who reported that HE4 has a clear specificity
edge over CA125 and also a better sensitivity for EOC, in
general and in the early stages patients [26-30].
HE4 as well as CA125 are not only found in ovarian car-
cinoma; abnormal levels may be also found in some be-
nign conditions or other gynecologic and non-gynecologic
malignancies; for example, breast, pancreatic, and endo-
metrial cancers. These results imply that HE4 and CA125













r =0.5, P <0.01
Figure 2 Correlation (Spearman) between HE4 and CA125 on
all groups.Another study demonstrated that HE4 might be asso-
ciated with the innate immune defenses of the lung,
nasal and oral cavities [32]. Several researchers have also
investigated the usefulness of HE4 in other malignancies,
including transitional cell carcinoma of the urinary tract
and endometrial cancer [33].
The limits of any single tumor marker for EOC have
been addressed in several recent experiences, in which a
multimarker approach has been pursued in order to
achieve a better diagnostic accuracy [34-38]. Combined
the two markers showed improved sensitivity to 96.7%,
and increased PPV. There was a 12.4% increase in PPV
for CA125 compared to HE4 (16.3% vs. 3.9%). Improv-
ing the PPV not only means less inappropriate referrals
and its associated costs, but also a reduction in the num-
ber of midline laparotomies, which is still the standard
for cares for women with suspected EOC.
The correlation between HE4 and CA125 levels was
estimated using Spearman’s rank correlation test, most
of the measured values tended to be increased for both
markers. However, the degree of correlation was not so
strong (r = 0.5), and there were some discordant results.
These mean that each marker was elevated concurrentlyTable 4 Levels of HE4 and CA125 in the ovarian cancer
group before and after treatment
Before treatment After treatment P value
HE4 237.2 (34.3-4090) 91.9 (45.4-180) <0.001
CA125 295.5 (4.2-1781) 11.6 (4-71.5) <0.001
Figure 3 HE4 and CA125 in the ovarian cancer group before
and after treatment.
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port the necessity of combining the two markers.
The increases in both markers were more evident in cer-
tain histologies of ovarian cancer than in others. Galgano
et al. reported that HE4 proteins or genes were expressed
strongly in serous papillary, clear cell, and endometrioid
carcinoma of the ovaries. However, other histologies of
ovary cancer or non-gynecologic malignancies including
invasive ductal carcinoma of breast, endometrial, pancrea-
ticobiliary, and renal cell carcinoma also exhibited strong
or weak expressions of HE4 proteins [15]. In our result, the
predominant histological type observed is serous followed
by endometriod and mucinous, we found both tumor mar-
kers HE4 and CA125 were related to tumor stage and
histological types with the lowest concentration in mucin-
ous subtype (median 66 U/ml, for CA125, and median 159
pmol/l, for HE4) and elevation of HE4 or CA125 was obvi-
ous in serous subtypes (median 285 U/ml, for CA125, and
median 305 pmol/l, for HE4) but was not evident in other
histological type. Kobel et al. investigated the variation in
expression of 21 different markers in accordance with
ovarian cancer subtypes, and concluded that most markers
differ significantly between histological types [39].
In assessment of treatment response both CA125 and
HE4 levels show significant difference before and after
chemotherapy (P < 0.001) for both, in which normalization
of CA125 and HE4 levels occurred. Relevant thresholds
for using these markers for remission monitoring have not
been established. There is an established threshold range
for various commercial CA125 assays [40]. Thresholds for
HE4 have been reported only recently but remain uncer-
tain [41-43]. In three patients CA125 and HE4 dropped
but remained above their respective thresholds thereafter
(one patient had high CA125 and others had high HE4).
HE4 serum levels are related to progression of disease
stage [44] and hence to tumor burden. A failure of HE4
levels to normalize at the completion of primary therapy
could be related to persistent disease not detected byCA125 nor by physical exam or CT imaging. These
patients may represent a high risk group who could poten-
tially benefit from additional treatment or more intensive
monitoring. Confirmation of this HE4 behavior in a larger
number of patients is therefore required.
In addition to the search of specific markers for the de-
termination of the early stages of any cancer form, it is just
as important to find markers capable of following the re-
mission from disease as response to therapy. The sugges-
tion that HE4 is a good indicator for the remission from
the disease was reported by a follow up study by Allard
et al. in which it was shown that the values of HE4 corre-
lated with the clinical response to treatment or remission
from the disease, as documented by CT imaging [45].
Conclusion
HE4 demonstrated comparable diagnostic performances
to CA125 as a tumor marker for detecting ovarian can-
cer. HE4 was more sensitive in detecting early stages of
ovarian cancer and more specific. HE4 improves the util-
ity of CA125 as a tumor marker in ovarian cancer, and
using both markers simultaneously increases the tumor
marker sensitivity. The use of this combination might
enable to improve detection of ovarian cancer as com-
pared with use of either marker alone for the discrimin-
ation of benign from malignant ovarian lesions.
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